Biomarkers to Predict Aggressive Prostate Cancer

Video   Mar 31, 2015


About the Speaker
Claire gained her PhD in 2002 and since then has worked in the field of cancer research. Claire has previously held a post at the prestigious MRC Cancer Cell Unit in Cambridge, UK before returning to Swansea University. Claire is now based at the Institute of Life Science where one of her research aims is concerned with identifying prognostic biomarkers for clinical management of prostate cancer and pancreatic cancer patients. Claire is also a Senior Lecturer in Genetics and teaches on the Genetics and Medical Genetics BSc degree schemes and Graduate Entry Medicine in the College of Medicine.Abstract
Prostate cancer (CaP) is the most common cancer in men in the UK. Every year nearly 40,000 cases of CaP are diagnosed and it accounts for approximately 12% of all male deaths from cancer in the UK. Early diagnosis of organ-confined CaP is essential since radical prostatectomy or radiotherapy offers the only chance of complete cure and treatment of advanced disease is palliative and in-effective (in the long term). In addition, early organ-confined CaP is not always life threatening and can follow and indolent course which does not require treatment. It is generally accepted that currently available methods used for diagnosis and staging of CaP (prostate specific antigen levels, Gleason score and clinical and pathological grade) lack the sensitivity to distinguish between patients with indolent, organ-confined CaP, those requiring radical treatment and those at risk of relapse after radical treatment. Clearly there is a need to identify molecular markers of CaP progression, invasion and metastasis to predict diagnosis and guide therapy. Due to the heterogeneous nature of cancer, analysis of single molecules provides limited information and it is impossible to diagnose cancer or predict disease progression using a single biomarker. Therefore there is a need to a identify a panel of biomarkers that may distinguish indolent cancer from aggressive metastatic disease when used collectively


Recommended Videos

CAR T-Cell Therapy: How Does It Work?


CAR T-cell therapy, like all forms of cancer immunotherapy, seeks to sharpen and strengthen the immune system’s inherent cancer-fighting powers. It involves treating patients with modified versions of their own immune system T cells.


How Does Cancer Immunotherapy Work?


Traditionally, cancer treatment has revolved around chemotherapy, radiation and surgery. But thanks to groundbreaking immune checkpoint blockade research led by Jim Allison, Ph.D., we have a new way to treat cancer: immunotherapy. Rather than treating the cancer directly, immunotherapy trains the immune system to attack cancer.


Here’s What We Learned From 83,000 Brain Scans


The most important lesson from 83,000 brain scans.



Comments | 0 ADD COMMENT

Like what you just watched? You can find similar content on the communities below.


To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free